Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post Herpetic Neuralgia Clear all
Completed Phase 2 Interventional

A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)

NCT00576108
View directory record Official record
Conditions
Postherpetic Neuralgia, Shingles, Herpes Zoster, Neuropathic Pain
Interventions
KD7040 Topical Gel, Placebo gel
Drug
Lead sponsor
Kalypsys, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2008 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

NCT00034710
View directory record Official record
Conditions
Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions
Capsaicin Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2006 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
RN624, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Anniston, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

[S,S]-Reboxetine Dose-Range Finding Trial

NCT00288652
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Early Phase 1 Interventional

3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)

NCT03421613
View directory record Official record
Conditions
Treatment of PHN
Interventions
3VM1001, Placebo
Drug · Other
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

NCT00916942
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
capsaicin 8%, Lidocaine (2.5%)/Prilocaine (2.5%) Cream
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Naples, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2009 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 24, 2026, 12:45 AM EDT
Terminated Phase 2 Interventional Results available

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

NCT01886313
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Nasal Spray, Placebo
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Santa Monica, California • Lauderdale Lakes, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

NCT00617461
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
GEn 1200mg/day, GEn 3600mg/day
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Oxnard, California • Roseville, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

NCT01757873
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Z160, Placebo
Drug
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Sep 24, 2026, 12:45 AM EDT
Terminated Phase 2 Interventional

[S,S]-Reboxetine Add-On Trial

NCT00334685
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine + Pregabalin, Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Huntsville, Alabama • Gilbert, Arizona • North Dartmouth, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Shingles Prevention Study

NCT00007501
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Varicella-zoster vaccine, Placebo
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
38,456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)

NCT02365636
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
TV-45070, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

NCT01223365
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
54
States / cities
Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia

NCT01318226
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ATx08-001, Placebo
Drug
Lead sponsor
Aestus Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
9
States / cities
Chandler, Arizona • Peoria, Arizona • Cutler Bay (Miami), Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)

NCT00609323
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
lidocaine and tetracaine cream 7%/7%, Placebo
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Lexington, Kentucky • High Point, North Carolina • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation for Facial Pain

NCT02633306
View directory record Official record
Conditions
Trigeminal Nerve Injuries, Post-herpetic Neuralgia, Facial Pain, Nervus Intermedius Neuralgia
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 110 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Vaporized Marijuana on Neuropathic Pain

NCT01037088
View directory record Official record
Conditions
Neuropathic Pain, Reflex Sympathetic Dystrophy, Peripheral Neuropathy, Post-herpetic Neuralgia, Spinal Cord Injury, Multiple Sclerosis
Interventions
Mild dose cannabis, Low dose cannabis, Cannabis
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 24, 2026, 12:45 AM EDT
Not yet recruiting Phase 1 Interventional

Simultaneous Engagement of Networks for Alleviating Pain (SENAP)

NCT07057206
View directory record Official record
Conditions
Neuropathic Pain, Postherpetic Neuralgia
Interventions
PFM-guided cortical stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 24, 2026, 12:45 AM EDT
Completed No phase listed Observational Results available

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

NCT01426230
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
Not listed
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 24, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Dextromethorphan Versus Placebo for Neuropathic Pain

NCT00001344
View directory record Official record
Conditions
Diabetic Neuropathies, Herpes Zoster, Neuralgia
Interventions
dextromethorphan
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 12:45 AM EDT
Active, not recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for Chronic Neuropathic Pain

NCT05593237
View directory record Official record
Conditions
Chronic Neuropathic Pain, Post-Stroke Pain, Trigeminal Neuralgia, Nerve Injury, Spinal Cord Injuries, Pain, Postoperative, Complex Regional Pain Syndromes, Post-herpetic Neuralgia, Nerve Root Avulsion
Interventions
High Frequency rTMS, Low Frequency rTMS
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 24, 2026, 12:45 AM EDT